RNA sequencing steps toward the first line


Editorial


doi: 10.1002/cncr.34801.


Online ahead of print.

Affiliations

Item in Clipboard

Editorial

Theresa A Boyle et al.


Cancer.


.

Abstract

DNA is the sequence that codes for proteins. Messenger RNA is transcribed from the DNA sequence of genes and translated into protein. It can be difficult to predict how a change in the DNA sequence will affect messenger RNA and protein quantity and quality. DNA translocation changes can cause the joining of sequences from two different genes or different parts of the same gene. DNA sequencing is often used clinically to predict how DNA changes might affect proteins. Alternatively, RNA sequencing can be used as a more direct measure of the effect of DNA changes on the protein products. This sequencing is important for identifying changes in cancer that may indicate response to targeted therapy, prognosis, or diagnosis.


Keywords:

RNA sequencing; biomarkers; fusion protein; next-generation sequencing (NGS); nonsmall cell lung cancer; splice variant; targeted therapy; translocation.

References

REFERENCES

    1. Latysheva NS, Babu MM. Discovering and understanding oncogenic gene fusions through data intensive computational approaches. Nucleic Acids Res. 2016;44(10):4487-4503. doi:10.1093/nar/gkw282

    1. Davies KD, Lomboy A, Lawrence CA, et al. DNA-based versus RNA-based detection of MET exon 14 skipping events in lung cancer. J Thorac Oncol. 2019;14(4):737-741. doi:10.1016/j.jtho.2018.12.020

    1. Li W, Liu Y, Li W, Chen L, Ying J. Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in NSCLC. J Thorac Oncol. 2020;15(7):1223-1231. doi:10.1016/j.jtho.2020.02.023

    1. Li W, Wan R, Guo L, et al. Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer. BMC Med. 2022;20(1):160. doi:10.1186/s12916-022-02362-9

    1. Ju S, Cui Z, Hong Y, et al. Detection of multiple types of cancer driver mutations using targeted RNA sequencing in nonsmall cell lung cancer. Cancer. 2023;000:000-000. doi:10.1002/cncr.34804

Read more here: Source link